Prognostic impact of cytogenetic aberrations in patients with multiple myeloma or monoclonal gammopathy of unknown significance.
Chromosomal aberrations are the most important prognostic factors in haematological malignancies. Detection of certain genetic changes leads to risk adapted strategies in leukaemia therapy. In multiple myeloma the importance of genetic alterations and their prognostic impact is of growing interest. Several therapeutic approaches seem to be uneffective for patients harbouring certain chromosomal abnormalities. Although the yield of metaphases due to a low proliferation rate is considerably lower in plasma cell dyscrasias, a number of chromosomal changes with prognostic implications have been identified in the past years, particularly due to the introduction of new techniques. This article gives a short survey of the most important genetic alterations and their prognostic influence on the outcome of patients with plasma cell malignancies known to date.
Schilling
Georgia
G
Medizinische Klinik II, Universitätsklinikum Hamburg-Eppendorf, Hamburg. g.schilling@uke.uni-hamburg.de
Dierlamm
Judith
J
Hossfeld
Dieter K
DK
D002869:Chromosome Aberrations; D002877:Chromosomes, Human / Q000235:genetics*; D006801:Humans; D007621:Karyotyping; D007938:Leukemia / Q000235:genetics / Q000473:pathology / Q000628:therapy; D008677:Metaphase; D009101:Multiple Myeloma / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D010950:Plasma Cells / Q000473:pathology; D011379:Prognosis; D016896:Treatment Outcome